PDCD1 and neoplasm: However, the clinical efficacy of PD-1/PD-L1 monoclonal antibodies relies on their target expression in the tumor microenvironment, exhibiting limited responses in patients with low PD-1/PD-L1 levels (Herbst et al., 2016; Akinleye and Rasool, 2019).